Crossmark

Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Crossref DOI link: https://doi.org/10.1186/s12885-019-5370-5

Published Online: 2019-02-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bergamino, Milana

Rullan, Antonio J.

Saigí, Maria

Peiró, Inmaculada

Montanya, Eduard

Palmero, Ramón

Ruffinelli, José Carlos

Navarro, Arturo

Arnaiz, María Dolores

Brao, Isabel

Aso, Samantha

Padrones, Susana

Cardenal, Felipe

Nadal, Ernest http://orcid.org/0000-0002-9674-5554
Funding

Funding for this research was provided by:

Department of Health Generalitat de Catalunya (SLT006/17/00127)

Instituto de Salud Carlos III (CM17/00180, PI14/01109)
License Information

Text and Data Mining valid from 2019-02-21
More Information

Article History

Received: 26 July 2018

Accepted: 11 February 2019

First Online: 21 February 2019

Ethics approval and consent to participate

: The protocol of this study was approved by the ethics committee of the Hospital Universitari de Bellvitge.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below